View Future GrowthIterum Therapeutics 過去の業績過去 基準チェック /06Iterum Therapeuticsは28.1%の年平均成長率で業績を伸ばしているが、Pharmaceuticals業界はgrowingで10.3%毎年増加している。売上は成長しており、年平均109.1%の割合である。主要情報28.11%収益成長率73.99%EPS成長率Pharmaceuticals 業界の成長5.95%収益成長率109.13%株主資本利益率n/aネット・マージン-6,913.08%前回の決算情報30 Sep 2025最近の業績更新Iterum Therapeutics plc to Report Q3, 2025 Results on Nov 14, 2025Nov 07Iterum Therapeutics plc to Report Q2, 2025 Results on Aug 05, 2025Jul 29Iterum Therapeutics plc to Report Q1, 2025 Results on May 13, 2025May 06Iterum Therapeutics plc to Report Q4, 2024 Results on Feb 07, 2025Jan 31Iterum Therapeutics plc to Report Q3, 2024 Results on Nov 14, 2024Nov 11Iterum Therapeutics plc to Report Q2, 2024 Results on Aug 14, 2024Aug 08すべての更新を表示Recent updatesIterum Therapeutics plc(OTCPK:ITRM.F) dropped from NASDAQ Composite IndexApr 02Iterum Therapeutics to Be Delisted from Nasdaq Following Withdrawal of AppealMar 31New major risk - Share price stability Mar 04Iterum Therapeutics Receives A Delisting Determination Letter from the Nasdaq Stock MarketMar 03Iterum Therapeutics plc Provides Business UpdateFeb 13Iterum Therapeutics plc Receives Notice of Non-Compliance with Nasdaq Listing RequirementsDec 13New minor risk - Profitability Dec 07Iterum Therapeutics plc Receives 510(K) Clearance by the U.S. Food and Drug AdministrationNov 25Price target decreased by 27% to US$5.50 Nov 20New minor risk - Share price stability Nov 17Iterum Therapeutics plc to Report Q3, 2025 Results on Nov 14, 2025Nov 07Iterum Therapeutics plc Receives Letter of Non-Compliance with Nasdaq's Minimum Bid Price RuleAug 29Iterum Therapeutics Plc Launches ORLYNVAH, the First and Only Oral Penem Antibody in the U.SAug 20New major risk - Financial position Aug 06Iterum Therapeutics plc to Report Q2, 2025 Results on Aug 05, 2025Jul 29Iterum Therapeutics plc, Annual General Meeting, Sep 10, 2025Jul 21Iterum Therapeutics plc Appoints Christine Coyne as Chief Commercial OfficerJun 30New minor risk - Profitability May 13No longer forecast to breakeven May 13Iterum Therapeutics plc to Report Q1, 2025 Results on May 13, 2025May 06Iterum Therapeutics plc has completed a Follow-on Equity Offering in the amount of $4.974845 million.May 01New minor risk - Share price stability Apr 30Iterum Therapeutics plc has filed a Follow-on Equity Offering in the amount of $4.974845 million.Apr 29Consensus revenue estimates fall by 20% Apr 06No longer forecast to breakeven Apr 06New minor risk - Profitability Apr 04Iterum Therapeutics plc Announces Board and Committee AppointmentsMar 10Iterum Therapeutics Notifies Nasdaq Regarding Non-Compliance with the Audit Committee RequirementFeb 15+ 1 more updateForecast to breakeven in 2027 Feb 14Iterum Therapeutics plc to Report Q4, 2024 Results on Feb 07, 2025Jan 31Iterum Therapeutics Regains Full Nasdaq Compliance with Listing Rule 5550(b)Nov 22Iterum Therapeutics plc to Report Q3, 2024 Results on Nov 14, 2024Nov 11Iterum Therapeutics plc Receives U.S. FDA Approval of ORLYNVAH (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract InfectionsOct 25Iterum Therapeutics Receives Formal Notice from Nasdaq Panel to Consider its Appeal at an Oral Hearing on November 21, 2024Oct 15Iterum Therapeutics Receives Delisting Determination Letter from Nasdaq Regarding its Failure to Meet the Terms of the Extension to Comply with the Minimum Stockholders’ Equity RequirementOct 05New major risk - Shareholder dilution Aug 16Forecast to breakeven in 2026 Aug 15Iterum Therapeutics plc to Report Q2, 2024 Results on Aug 14, 2024Aug 08New major risk - Shareholder dilution Aug 05Iterum Therapeutics plc Broadens Patent Estate for Oral SulopenemAug 02New major risk - Financial position Jul 17Iterum Therapeutics plc Receives FDA Acceptance of Resubmission of NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract InfectionsJun 01Iterum Therapeutics plc Announces Executive ChangesMay 11Iterum Therapeutics plc to Report Q1, 2024 Results on May 13, 2024May 08Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral SulopenemApr 30Iterum Therapeutics plc, Annual General Meeting, Jun 19, 2024Apr 28Insufficient new directors Apr 01Iterum Therapeutics plc to Report Q4, 2023 Results on Mar 28, 2024Mar 22Iterum Therapeutics plc Announces Positive Topline Results from Its Phase 3 Reassure Clinical Trial of Oral Sulopenem in Un Complicated Urinary Tract InfectionsJan 30New major risk - Financial position Jan 22Iterum Therapeutics plc Announces the Resignation of Mark Chin as Director, Effective December 31, 2023Dec 30New major risk - Revenue and earnings growth Nov 16Iterum Therapeutics plc to Report Q3, 2023 Results on Nov 14, 2023Nov 08New minor risk - Share price stability Nov 01Iterum Therapeutics plc Announces Completion of Enrollment in its REASSURE Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract InfectionsOct 25Iterum Therapeutics Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock MarketOct 05Iterum Therapeutics plc to Report Q2, 2023 Results on Aug 11, 2023Aug 05Iterum Therapeutics plc, Annual General Meeting, May 03, 2023Feb 18Iterum Therapeutics plc to Report Q3, 2022 Results on Nov 10, 2022Nov 04Iterum Announces First Patient Dosed in Reassure, A Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract InfectionsOct 21Iterum Therapeutics plc Announces Issuance of Allowance for A U.S. Patent Covering Oral SulopenemSep 20Iterum Therapeutics Regains Compliance with Nasdaq Bid Price RuleSep 02Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?Aug 19Iterum Therapeutics Non-GAAP EPS of -$0.03 beats by $0.03 Aug 12Iterum Therapeutics plc Announces Special Protocol Assessment Agreement with the FDAJul 12Iterum jumps 64% as FDA agrees to Phase 3 trial for UTI candidate Jul 11Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?May 06Iterum Therapeutics plc, Annual General Meeting, Jun 15, 2022Apr 26Iterum Therapeutics plc to Report Q4, 2021 Results on Mar 28, 2022Mar 23Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?Jan 12Iterum Therapeutics Provides Update from FDA Type A Meeting Regarding Oral SulopenemOct 01Is Iterum Therapeutics (NASDAQ:ITRM) A Risky Investment?Sep 25Bernstein Liebhard Reminds Investors of the Deadline to File Lead Plaintiff Motion in Securities Class Action Lawsuit Filed Against Iterum Therapeutics plcSep 10Pomerantz Law Firm Announces the Filing of Class Action against Iterum Therapeutics plc and Certain OfficersAug 06Despite Risks Around Regulatory Approval, Iterum Therapeutics Rates A Speculative Buy Jul 05Iterum Therapeutics plc Receives Letter from the U.S. Food and Drug Administration as Part of Their Ongoing Review of the New Drug Application for sulopenem etzadroxil/probenecidJul 03Independent Director Mohammed Shahzad Malik has left the company Jun 21It's Unlikely That The CEO Of Iterum Therapeutics plc (NASDAQ:ITRM) Will See A Huge Pay Rise This YearJun 11Consensus forecasts updated May 29Iterum Therapeutics plc Provides Update on NDA ReviewMay 28Is Iterum Therapeutics (NASDAQ:ITRM) Using Debt Sensibly?May 20Price target increased to US$2.00 Mar 20Consensus revenue estimates increase to US$2.86m Mar 19Independent Director has left the company Mar 18Iterum Therapeutics Appoints Beth P. Hecht to Board of DirectorsMar 17Iterum Therapeutics plc to Report Q4, 2020 Results on Mar 12, 2021Mar 06New 90-day high: US$2.27 Feb 10Have Insiders Been Selling Iterum Therapeutics plc (NASDAQ:ITRM) Shares?Feb 04This Insider Has Just Sold Shares In Iterum Therapeutics plc (NASDAQ:ITRM)Feb 04Iterum Therapeutics plc Announces Collaboration with Eversana to Support Oral Sulopenem LaunchFeb 02President recently sold US$148k worth of stock Jan 29Iterum Therapeutics plc Announces U.S. FDA Filing Acceptance of New Drug Application for Oral SulopenemJan 26New 90-day high: US$1.23 Jan 09Iterum Therapeutics plc Announces Executive ChangesDec 24Earnings beat expectations Nov 18Iterum Therapeutics plc has completed a Follow-on Equity Offering in the amount of $17.385884 million.Oct 29New 90-day low: US$0.53 Oct 24Iterum Therapeutics plc Plans to Proceed with an NDA Submission for sulopenem etzadroxil/probenecidOct 04Iterum Therapeutics plc has completed a Composite Units Offering in the amount of $6.374 million.Sep 01収支内訳Iterum Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:ITRM.F 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費30 Sep 250-2716430 Jun 250-2411631 Mar 250-239731 Dec 240-2581030 Sep 240-3181930 Jun 240-2883131 Mar 240-3683831 Dec 230-3874030 Sep 230-3183630 Jun 230-5692631 Mar 230-51112131 Dec 220-44131830 Sep 220-44141530 Jun 220-11141331 Mar 2204141231 Dec 210-92141130 Sep 210-9913930 Jun 210-115121131 Mar 210-135111431 Dec 200-52112130 Sep 200-64114030 Jun 200-84126431 Mar 200-99118331 Dec 190-103119130 Sep 190-104129130 Jun 191-97118631 Mar 191-85107531 Dec 181-7796930 Sep 181-6275530 Jun 181-4564031 Mar 181-3653231 Dec 171-29425質の高い収益: ITRM.Fは現在利益が出ていません。利益率の向上: ITRM.Fは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: ITRM.Fは利益を出していないが、過去 5 年間で年間28.1%の割合で損失を削減してきた。成長の加速: ITRM.Fの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: ITRM.Fは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( -3.2% ) と比較することは困難です。株主資本利益率高いROE: ITRM.Fの負債は資産を上回っているため、自己資本利益率を計算することは困難です。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/04/30 10:52終値2026/04/30 00:00収益2025/09/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Iterum Therapeutics plc 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7 アナリスト機関Adnan ButtGuggenheim Securities, LLCAntonio ArceH.C. Wainwright & Co.Matthew KellerH.C. Wainwright & Co.4 その他のアナリストを表示
Iterum Therapeutics plc has completed a Follow-on Equity Offering in the amount of $4.974845 million.May 01
Iterum Therapeutics plc has filed a Follow-on Equity Offering in the amount of $4.974845 million.Apr 29
Iterum Therapeutics Notifies Nasdaq Regarding Non-Compliance with the Audit Committee RequirementFeb 15+ 1 more update
Iterum Therapeutics plc Receives U.S. FDA Approval of ORLYNVAH (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract InfectionsOct 25
Iterum Therapeutics Receives Formal Notice from Nasdaq Panel to Consider its Appeal at an Oral Hearing on November 21, 2024Oct 15
Iterum Therapeutics Receives Delisting Determination Letter from Nasdaq Regarding its Failure to Meet the Terms of the Extension to Comply with the Minimum Stockholders’ Equity RequirementOct 05
Iterum Therapeutics plc Receives FDA Acceptance of Resubmission of NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract InfectionsJun 01
Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral SulopenemApr 30
Iterum Therapeutics plc Announces Positive Topline Results from Its Phase 3 Reassure Clinical Trial of Oral Sulopenem in Un Complicated Urinary Tract InfectionsJan 30
Iterum Therapeutics plc Announces the Resignation of Mark Chin as Director, Effective December 31, 2023Dec 30
Iterum Therapeutics plc Announces Completion of Enrollment in its REASSURE Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract InfectionsOct 25
Iterum Therapeutics Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock MarketOct 05
Iterum Announces First Patient Dosed in Reassure, A Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract InfectionsOct 21
Iterum Therapeutics plc Announces Issuance of Allowance for A U.S. Patent Covering Oral SulopenemSep 20
Bernstein Liebhard Reminds Investors of the Deadline to File Lead Plaintiff Motion in Securities Class Action Lawsuit Filed Against Iterum Therapeutics plcSep 10
Pomerantz Law Firm Announces the Filing of Class Action against Iterum Therapeutics plc and Certain OfficersAug 06
Iterum Therapeutics plc Receives Letter from the U.S. Food and Drug Administration as Part of Their Ongoing Review of the New Drug Application for sulopenem etzadroxil/probenecidJul 03
It's Unlikely That The CEO Of Iterum Therapeutics plc (NASDAQ:ITRM) Will See A Huge Pay Rise This YearJun 11
Iterum Therapeutics plc Announces U.S. FDA Filing Acceptance of New Drug Application for Oral SulopenemJan 26
Iterum Therapeutics plc has completed a Follow-on Equity Offering in the amount of $17.385884 million.Oct 29
Iterum Therapeutics plc Plans to Proceed with an NDA Submission for sulopenem etzadroxil/probenecidOct 04
Iterum Therapeutics plc has completed a Composite Units Offering in the amount of $6.374 million.Sep 01
